Targeting the mitogen-activated protein kinase cascade to treat cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15573115.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The RAS-mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?
Medical subject headings
- Mitogen-Activated Protein Kinases
- Neoplasms